BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31838216)

  • 1. Do genetic polymorphisms of B-cell CLL/lymphoma 2 confer susceptibility to anti-tuberculous therapy-associated drug-induced liver injury?
    Lyu M; Jiao L; Zhou J; Li H; Meng Z; Xie W; Ren J; Bian Q; Ying B
    Int J Infect Dis; 2020 Feb; 91():223-231. PubMed ID: 31838216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genetic variants in calcium signaling related genes influence anti-tuberculosis drug induced liver injury: A prospective study.
    Lyu M; Zhou J; Chen H; Bai H; Song J; Liu T; Cheng Y; Ying B
    Medicine (Baltimore); 2019 Nov; 98(44):e17821. PubMed ID: 31689868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.
    Yuliwulandari R; Susilowati RW; Wicaksono BD; Viyati K; Prayuni K; Razari I; Kristin E; Syafrizal ; Subagyo ; Sri Diana E; Setiawati S; Ariyani A; Mahasirimongkol S; Yanai H; Mushiroda T; Tokunaga K
    J Hum Genet; 2016 Jun; 61(6):533-7. PubMed ID: 26911349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of LEPR polymorphisms with predisposition and inflammatory response in anti-tuberculosis drug-induced liver injury: A pilot prospective investigation in Western Chinese Han population.
    Zhao Z; Peng W; Zhou J; Zhou Y; Liu T; Bai H; Wu Q; Song J; Wu L; Song X; Ying B
    Infect Genet Evol; 2019 Nov; 75():103970. PubMed ID: 31325611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms in PXR and NF-κB1 influence susceptibility to anti-tuberculosis drug-induced liver injury.
    Zhang J; Zhao Z; Bai H; Wang M; Jiao L; Peng W; Wu T; Liu T; Chen H; Song X; Wu L; Hu X; Wu Q; Zhou J; Song J; Lyv M; Ying B
    PLoS One; 2019; 14(9):e0222033. PubMed ID: 31490979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible association of HMOX1 and NQO1 polymorphisms with anti-tuberculosis drug-induced liver injury: A matched case-control study.
    Yang M; Zhang H; Tao B; Pan H; Lu L; Yi H; Tang S
    J Clin Pharm Ther; 2019 Aug; 44(4):534-542. PubMed ID: 30776144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of POR and PPARα polymorphisms with risk of anti-tuberculosis drug-induced liver injury in Western Chinese Han population.
    Zhang C; Jiao L; Bai H; Zhao Z; Hu X; Wang M; Wu T; Peng W; Liu T; Song J; Zhou J; Li M; Lyv M; Zhang J; Chen H; Chen J; Ying B
    Infect Genet Evol; 2020 Apr; 79():104147. PubMed ID: 31857256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-nucleotide polymorphisms of
    Yang WN; Pang LL; Zhou JY; Qiu YW; Miao L; Wang SY; Liu XZ; Tan KA; Shi WW; Wang GQ; Hou FQ
    World J Gastroenterol; 2020 Mar; 26(12):1329-1339. PubMed ID: 32256020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.
    Perwitasari DA; Darmawan E; Mulyani UA; Vlies PV; Alffenaar JC; Atthobar J; Wilffert B
    Int J Mycobacteriol; 2018; 7(4):380-386. PubMed ID: 30531039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
    Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. rs1800796 of the IL6 gene is associated with increased risk for anti-tuberculosis drug-induced hepatotoxicity in Chinese Han children.
    Li Y; Tang H; Qi H; Shen C; Sun L; Li J; Xu F; Jiao W; Yang X; Shen A
    Tuberculosis (Edinb); 2018 Jul; 111():71-77. PubMed ID: 30029918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collagen type XVIII alpha 1 chain (COL18A1) variants affect the risk of anti-tuberculosis drug-induced hepatotoxicity: A prospective study.
    Cheng Y; Jiao L; Li W; Wang J; Lin Z; Lai H; Ying B
    J Clin Lab Anal; 2021 Feb; 35(2):e23630. PubMed ID: 33296124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK.
    Abbara A; Chitty S; Roe JK; Ghani R; Collin SM; Ritchie A; Kon OM; Dzvova J; Davidson H; Edwards TE; Hateley C; Routledge M; Buckley J; Davidson RN; John L
    BMC Infect Dis; 2017 Mar; 17(1):231. PubMed ID: 28340562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting antitubercular drug-induced liver injury and its outcome and introducing a novel scoring system.
    Raj Mani SS; Iyyadurai R; Mishra AK; Manjunath K; Prasad J; Lakshmanan J; Yadav B; Reginald A; Jasmine S; Hansdak SG; Zachariah A
    Int J Mycobacteriol; 2021; 10(2):116-121. PubMed ID: 34558461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the genetic variant FECH rs11660001 in the occurrence of anti-tuberculosis drug-induced liver injury.
    Zhang M; Zhu J; Wang N; Liu W; Lu L; Pan H; He X; Yi H; Tang S
    J Clin Pharm Ther; 2022 Aug; 47(8):1276-1283. PubMed ID: 35470464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting drug-induced liver injury from anti-tuberculous medications by early monitoring of liver tests.
    Patterson B; Abbara A; Collin S; Henderson M; Shehata M; Gorgui-Naguib H; Lynn W; Kon OM; John L
    J Infect; 2021 Feb; 82(2):240-244. PubMed ID: 33271167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between NR1I2 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity in an Eastern Chinese Han population: A case-control study.
    Yang M; Pan H; Chen H; Liu W; Lu L; He X; Yi H; Tang S
    Infect Genet Evol; 2020 Sep; 83():104349. PubMed ID: 32387752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association study of UGT1A9 promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population.
    Jiang J; Zhang X; Huo R; Li X; Yang Y; Gai Z; Xu M; Shen L; Cai L; Wan C; Li B; He L; Qin S
    Pharmacogenomics J; 2015 Aug; 15(4):326-31. PubMed ID: 25446781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of
    Thomas L; Raju AP; Chaithra S; Kulavalli S; Varma M; Sv CS; Baneerjee M; Saravu K; Mallayasamy S; Rao M
    Expert Rev Clin Pharmacol; 2024 Mar; 17(3):263-274. PubMed ID: 38287694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between BACH1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort.
    Zhang H; Qian H; Tao B; Yang M; Gong J; Yi H; Tang S
    Infect Genet Evol; 2018 Dec; 66():217-221. PubMed ID: 30316884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.